The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Assessing Pre-clinical Efficacy of Brain-penetrant TRPML1 Agonists to Treat Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is characterized by the accumulation of misfolded and aggregated alpha-synuclein inside neurons in the brain. This may either arise from, or be exacerbated by...
-
MRI Biomarkers Program, 2025Evaluation of Neuromelanin-sensitive, Quantitative Susceptibility Mapping and Free Water Imaging as Biomarkers of Nigral Dopaminergic Dysfunction
Study Rationale: This project seeks to validate three magnetic resonance imaging biomarkers capable of detecting and monitoring the degeneration of neurons in the substantia nigra in Parkinson’s...
-
Research Grant, 2025FUN-MITO: Functional Validation of Mitochondrial Polygenic Risk Scores in the PPMI Cohort
Study Rationale: In the majority of people with Parkinson's disease (PWP), the movement disorder is not caused by mutations in a single gene. Until recently, these people were considered “sporadic”...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Pre-clinical Development of Novel GCase Variants for Treating Parkinson’s Disease
Study Rationale: The most prevalent genetic risk factors for Parkinson’s Disease (PD) are mutations in GBA1, the gene that encodes the glucocerebrosidase (GCase) enzyme. Dysfunction of GCase leads to...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025CT600 as a Neuroprotective Peptide Therapeutic for Parkinson’s Disease
Study Rationale: Excess CDK5 protein kinase activity in the brain caused by the binding of CDK5 with another protein called P25 has been connected to Parkinson's disease. The CDK5-P25 interaction can...
-
MRI Biomarkers Program, 2025Validate Diffusion MRI Biomarkers of Early PD: A Multi-cohort Study of Free-water and CDM Measure
Study Rationale: Parkinson’s disease and related synucleinopathies, such as Dementia with Lewy Bodies, are challenging to diagnose at their earliest stages due to subtle initial symptoms. Our research...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.